Natera (NASDAQ:NTRA) Releases Earnings Results, Misses Expectations By $0.14 EPS

08 Nov 2026, 04:56 by Mitch Edgeman · The Markets Daily

Natera (NASDAQ:NTRA – Get Free Report) posted its quarterly earnings data on Thursday. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14), FiscalAI reports. The company had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. Natera had a negative return on equity of 8.73% and a negative net margin of 5.66%. The business’s revenue for the quarter was up 34.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.64) EPS.

Here are the key takeaways from Natera’s conference call:

Natera reported a record quarter, processing about 1.09 million tests, up 22%, and generating $794 million in revenue, up 34% year over year—or more than 40% excluding revenue true-ups. Clinical MRD volumes rose 56% to approximately 316,000 units.
The company raised its 2026 revenue guidance to $3.005 billion–$3.035 billion, an increase of $140 million at the midpoint. It also reported 65% gross margin and said losses narrowed while it generated cash.
Management highlighted new Medicare coverage for Signatera surveillance in early-stage liver cancer, nine to ten additional MolDX submissions in progress, and plans to launch colorectal and bladder cancer testing in Japan pending reimbursement and pricing. Executives said the coverage pipeline could support further Signatera ASP growth, though timing and outcomes remain uncertain.
Natera set a goal of doubling revenue to $6 billion by 2029, primarily through continued growth in oncology testing, higher Signatera ASPs, international expansion, and pharma and data services. Management expects early cancer detection to contribute relatively little to that target in 2028–2029.
The company plans to increase investment to support clinical trials, pharma and data demand, and early cancer detection; operating expenses are expected to grow 10%–12% in 2027. Management also cautioned that newer products may weigh on near-term costs and gross margins, although it expects cost improvements over time.

Natera Trading Down 14.6%

NTRA stock traded down $53.09 during trading hours on Friday, hitting $310.67. 5,775,619 shares of the stock traded hands, compared to its average volume of 1,711,005. The stock has a 50-day simple moving average of $380.25 and a 200 day simple moving average of $269.68. The company has a market cap of $44.78 billion, a P/E ratio of -272.52 and a beta of 1.55. Natera has a one year low of $181.00 and a one year high of $437.41.

Analyst Upgrades and Downgrades

A number of research firms have commented on NTRA. Canaccord Genuity Group boosted their price target on shares of Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. UBS Group upped their price target on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Royal Bank Of Canada increased their price objective on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Stephens raised their price objective on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, BTIG Research raised their price objective on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $391.69.

Get Our Latest Analysis on Natera

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Chapman sold 3,801 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the sale, the chief executive officer directly owned 87,431 shares of the company’s stock, valued at approximately $36,004,085.80. This represents a 4.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,419 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the completion of the sale, the insider directly owned 101,323 shares of the company’s stock, valued at $41,519,125.71. The trade was a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 53,573 shares of company stock valued at $19,856,400 in the last ninety days. 5.05% of the stock is owned by insiders.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Natera Company Profile

(Get Free Report)

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.